These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 32285171)
1. Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8 Jevtovic A; Pantic J; Jovanovic I; Milovanovic M; Stanojevic I; Vojvodic D; Arsenijevic N; Lukic ML; Radosavljevic GD Cancer Immunol Immunother; 2020 Aug; 69(8):1461-1475. PubMed ID: 32285171 [TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8 Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395 [TBL] [Abstract][Full Text] [Related]
3. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
4. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679 [TBL] [Abstract][Full Text] [Related]
5. Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha. Young MR; McCloskey G; Wright MA; Pak AS Cancer Immunol Immunother; 1994 Jan; 38(1):9-15. PubMed ID: 8299123 [TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. van Elsas A; Hurwitz AA; Allison JP J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624 [TBL] [Abstract][Full Text] [Related]
7. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680 [TBL] [Abstract][Full Text] [Related]
9. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752 [TBL] [Abstract][Full Text] [Related]
10. High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. Brandmaier AG; Leitner WW; Ha SP; Sidney J; Restifo NP; Touloukian CE J Immunother; 2009 Sep; 32(7):677-88. PubMed ID: 19561540 [TBL] [Abstract][Full Text] [Related]
11. Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells. Sauer KA; Maxeiner JH; Karwot R; Scholtes P; Lehr HA; Birkenbach M; Blumberg RS; Finotto S J Immunol; 2008 Nov; 181(9):6148-57. PubMed ID: 18941205 [TBL] [Abstract][Full Text] [Related]
12. Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells enhances the recruitment of CD11b(+) myeloid cells to the lungs and facilitates B16-F10 melanoma colonization. Souza LE; Almeida DC; Yaochite JN; Covas DT; Fontes AM Exp Cell Res; 2016 Jul; 345(2):141-9. PubMed ID: 26027946 [TBL] [Abstract][Full Text] [Related]
13. Adenosine A(2B) receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells. Kaji W; Tanaka S; Tsukimoto M; Kojima S J Toxicol Sci; 2014 Apr; 39(2):191-8. PubMed ID: 24646699 [TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner. Yu R; Jin L; Li F; Fujimoto M; Wei Q; Lin Z; Ren X; Jin Q; Li H; Meng F; Jin G J Dermatol Sci; 2020 Sep; 99(3):193-202. PubMed ID: 32859456 [TBL] [Abstract][Full Text] [Related]
15. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733 [TBL] [Abstract][Full Text] [Related]
16. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8 Yin W; Song Y; Liu Q; Wu Y; He R Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970 [TBL] [Abstract][Full Text] [Related]
17. The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma. de Almeida LY; Mariano FS; Bastos DC; Cavassani KA; Raphelson J; Mariano VS; Agostini M; Moreira FS; Coletta RD; Mattos-Graner RO; Graner E Cancer Chemother Pharmacol; 2020 Feb; 85(2):321-330. PubMed ID: 31863126 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy. Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573 [TBL] [Abstract][Full Text] [Related]
19. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2. Harada M; Matsuzaki G; Shinomiya Y; Kurosawa S; Ito O; Okamoto T; Takenoyama M; Sumitika H; Nishimura Y; Nomoto K Cancer Immunol Immunother; 1994 May; 38(5):332-8. PubMed ID: 8162615 [TBL] [Abstract][Full Text] [Related]
20. Innate and adoptive immune cells contribute to natural resistance to systemic metastasis of B16 melanoma. Umeshappa CS; Zhu Y; Bhanumathy KK; Omabe M; Chibbar R; Xiang J Cancer Biother Radiopharm; 2015 Mar; 30(2):72-8. PubMed ID: 25714591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]